Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease

Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease

This study will evaluate the response rate to treatment with pentostatin in steroid-refractory acute graft versus host disease.

Inclusion Criteria:

• Must have biopsy proven grade II-IV acute GVHD refractory to systemic corticosteroids
• No chronic GVHD
• Age ≥ 18 years
• Evidence of myeloid engraftment (ANC ≥ 0.5 x 109/l)
• Performance status 0-3

Exclusion Criteria:

• Patients on mechanical ventilation or who have resting O2 saturation <90% by pulse-oximetry.
• Patients on renal dialysis or who have an estimated creatinine clearance of < 30 ml/min/1.73 m2.
• Patients with documented clinical infection (progressive symptoms despite antibiotics or continued fever) cannot be enrolled on study until infection is controlled.